Nat Charoensook's questions to Viking Therapeutics Inc (VKTX) leadership • Q2 2025
Question
Nat Charoensook, on for Thomas Smith of Leerink Partners, asked what the amylin agonist program would need to demonstrate in its Phase I trial, particularly relative to VK2735, to justify continued development.
Answer
President & CEO Brian Lian stated that the goal for the Phase I amylin study is to see an impact on body weight and to understand the tolerability profile. He noted that the industry has matured beyond focusing solely on 28-day weight loss data, and the decision to proceed will be based on the overall trajectory, safety, and tolerability.